These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27856923)

  • 1. Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database.
    Matsumura C; Chisaki Y; Sakimoto S; Sakae H; Yano Y
    J Oncol Pharm Pract; 2018 Jan; 24(1):22-27. PubMed ID: 27856923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
    J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.
    Hasegawa S; Matsui T; Hane Y; Abe J; Hatahira H; Motooka Y; Sasaoka S; Fukuda A; Naganuma M; Hirade K; Takahashi Y; Kinosada Y; Nakamura M
    PLoS One; 2017; 12(7):e0182045. PubMed ID: 28732067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Adverse Drug Reaction Risk in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
    Chisaki Y; Aoji S; Yano Y
    Biol Pharm Bull; 2017; 40(6):824-829. PubMed ID: 28566626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
    Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
    Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study.
    Abdel-Rahman O; Wu C; Easaw J
    Future Oncol; 2021 Oct; 17(30):3977-3986. PubMed ID: 34342490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How much do we need to worry about venous thromboembolism after hospital discharge? A study of colorectal surgery patients using the National Surgical Quality Improvement Program database.
    Fleming FJ; Kim MJ; Salloum RM; Young KC; Monson JR
    Dis Colon Rectum; 2010 Oct; 53(10):1355-60. PubMed ID: 20847615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
    Kuk A; Magnowska M; Suchy W; Swierczynska J; Zaborowski MP; Gaca M; Nowak-Markwitz E
    Target Oncol; 2017 Aug; 12(4):495-503. PubMed ID: 28580507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.
    Mukai R; Hasegawa S; Umetsu R; Nakao S; Shimada K; Uranishi H; Masuta M; Suzuki H; Nishibata Y; Nakamura M
    J Clin Pharm Ther; 2019 Apr; 44(2):285-291. PubMed ID: 30569470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolism as the adverse event of combined oral contraceptives in Japan.
    Sugiura K; Kobayashi T; Ojima T
    Thromb Res; 2015 Dec; 136(6):1110-5. PubMed ID: 26475406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database.
    Kose E
    J Clin Pharm Ther; 2018 Aug; 43(4):543-549. PubMed ID: 29574893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.
    Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
    Sci Rep; 2022 Sep; 12(1):15619. PubMed ID: 36114412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyses of Respiratory Depression Associated with Opioids in Cancer Patients Based on the Japanese Adverse Drug Event Report Database.
    Sugawara H; Uchida M; Suzuki S; Suga Y; Uesawa Y; Nakagawa T; Takase H
    Biol Pharm Bull; 2019; 42(7):1185-1191. PubMed ID: 31257293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polypharmacy in elderly patients in Japan: Analysis of Japanese real-world databases.
    Mabuchi T; Hosomi K; Yokoyama S; Takada M
    J Clin Pharm Ther; 2020 Oct; 45(5):991-996. PubMed ID: 31986233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of the Relationship between Hypnotics and Delirium Using the Japanese Adverse Drug Event Report (JADER) Database].
    Kikuchi N; Hazama K; Imai T; Suzuki S; Yoshida Y; Hidaka S
    Yakugaku Zasshi; 2018; 138(7):985-990. PubMed ID: 29962478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis.
    Kanbayashi Y; Ishikawa T; Otsuji E; Takayama K
    Oncology; 2024; 102(7):604-610. PubMed ID: 38198783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients.
    Yu I; Chen L; Ruan JY; Chang JT; Cheung WY
    Support Care Cancer; 2016 Mar; 24(3):1199-208. PubMed ID: 26286113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
    O'Connell KA; Wood JJ; Wise RP; Lozier JN; Braun MM
    JAMA; 2006 Jan; 295(3):293-8. PubMed ID: 16418464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.